Soluble guanylate cyclase stimulators for heart failure: a network meta-analysis and subgroup analyses of reduced and preserved ejection fraction

Abuelazm, Mohamed T.; Attia, Abdelrahman; Abdelnabi, Mohamed; Jafar, Uzair; Almaadawy, Omar; Elzeftawy, Mohamed A.; Mahmoud, Abdelrahman; Albakri, Khaled; Abdelazeem, Basel

doi:10.1186/s43044-024-00437-x

The Egyptian Heart Journal

Table 1 Summary characteristics of the included RCTs

From: Soluble guanylate cyclase stimulators for heart failure: a network meta-analysis and subgroup analyses of reduced and preserved ejection fraction

Study ID	Study design	Country	Total participants	sGC stimulator				HF type/NYHA class	Primary outcome
Study ID	Study design	Country	Total participants	Drug	Dose	Times of administration	TTT duration	HF type/NYHA class	Primary outcome
Armstrong et al. 2020 (VITALITY-HFpEF) [8]	Phase IIb multicenter, double-blinded RCT	21 countries	789	Vericiguat	10 or 15 mg	Once daily	24 weeks	HFpEF/NYHA II & III	Kansas City Cardiomyopathy Questionnaire Physical Limitation Score (KCCQ PLS)
Armstrong et al. 2020 (VICTORIA) [2]	Phase III multicenter, double-blinded RCT	42 countries	5050	Vericiguat	10 mg	Once daily	N/A	HFrEF/NYHA II–IV	The composite of death from cardiovascular causes or first hospitalization for heart failure
Bonderman et al. 2013 (LEPHT) [10]	Phase IIb multicenter, double-blinded RCT	18 countries	201	Riociguat	0.5, 1, or 2 mg	Three times daily	16 weeks	HFrEF/NYHA II–IV	mPAP change
Bonderman et al. 2014 (DILATE-1) [7]	Phase II multicenter, double-blinded RCT	Austria, the Czech Republic, and Germany	39	Riociguat	0.5, 1, or 2 mg	Once daily	N/A	HFpEF	mPAP change
Dachs et al. 2022 (haemoDYNAMIC) [9]	Phase IIb multicenter, double-blinded RCT	Austria and Germany	114	Riociguat	0.5 mg (up-)titrated to 1.0 of 1.5 mg	Three times daily	30 weeks	HFpEF	CO change
Gheorghiade et al. 2015 (SOCRATES-Reduced) [9]	Multicenter, double-blinded RCT	Europe, North America, and Asia	456	Vericiguat	1.25, 2.5, 5, or 10 mg	Once daily	12 weeks	HFrEF/NYHA II–IV	NT-proBNP change
Pieske et al. 2017 (SOCRATES-PRESERVED) [12]	Multicenter, double-blinded RCT	United States and Germany	477	Vericiguat	1.25, 2.5, 5, or 10 mg	Once daily	12 weeks	HFpEF/NYHA II–IV	NT-proBNP change
Udelson et al. 2020 (CAPACITY HFpEF) [11]	Phase II multicenter, double-blinded RCT	United States and Canada	181	Praliciguat	40 mg	N/A	12 weeks	HFpEF/NYHA II–IV	Peak VO2 change

N/A not available, HF heart failure, sGC soluble guanylate cyclase, TTT treatment, NYHA New York Heart Association, HFrEF heart failure with reduced ejection fraction, HFpEF heart failure with preserved ejection fraction, CO cardiac output, mPAP mean pulmonary arterial pressure, NT-proBNP N-terminal pro-brain natriuretic peptide

Back to article page